Important note: Information in this article was accurate in August 2007. The state of the art may have changed since the publication date.
HIV Treatment Bulletin - Vol. 8, No. 8/9, August-September 2007
Simon Collins, HIV i-Base
Gerd Fätkenheuer and colleagues from University Hospital, Infectious Diseases, Köln, presented a poster on CD4 recovery in 15 patients (11 men, 4 women) who switched to an RTI-sparing combination, after not achieving immunological benefit (CD4 <250 cells/mm3) despite undetectable viral load for over 6 months. Original therapy was lopinavir/r (n=10), nelfinavir (n=1), efavirenz (n=1); background nucleosides were AZT/3TC (n=10), AZT/abacavir (n=1) and AZT/tenofovir (n=3).
Patients were switched to atazanavir (ATV) (300mg QD), saquinavir (SQV, 1000mg BID) and ritonavir (RTV, 100mg QD) and followed for 48 weeks. T cell activation (CD38+HLA-DR+) on CD4+ and CD8+ T- cells were longitudinally (0, 24 and 48 weeks) determined and compared to good immunologic (IgR) responders with ART (n=10) and patients with high CD4+ T cells without ART (n=9).
Baseline characteristics included median [IQR] CD4 count 197 cells/mm3 [130-220]; months on ART 20 [6-114]; and age 46 years[38-62].
Median CD4 cell count (and CD4 percentage) improved significantly to 230 cells/mm3 (14%), [170-290, 10-17%] and 260 cells/mm3 17% [195-415, 13.5-18.5%] at weeks 24 and 48 respectively. Only one patient discontinued the study. Viral load remained < 50 copies/mL in the remianing14 patients.
Activation markers did not change longitudinally or in comparison to IgR. Subjects with detectable HIV-RNA and high CD4+ T-cells demonstrated higher expression of CD38 on CD4+ and CD8+ T cells and HLA-DR on CD8+ T cells (p<0.05).
Comment
Although this is small, uncontrolled study, in patients who fail to show a CD4 response on recommended first-line regimens, this option may deserve further exploration.
In the symposium on HIV pathogenesis on the first day of the conference, Michael Lederman referenced a study showing that up to 20% patients fail to achieve CD4 increase to greater than 350 cells/mm3 after five years of suppressive therapy (below 95th percentile of HIV-negative population).[2]
References
| 1. | Lehmann C, Hofmann A, Fätkenheuer G et al. Recovery of CD4+ T cells after switch to a nucleoside free regimen in patients with poor immunologic response despite complete HIV-RNA suppression. IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th:(abstract no. WEPEB043). |
| 2. | Lederman M. How HIV makes you sick: mechanisms of CD4+ T cell loss and recovery. IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th:(abstract no. MOPL102). |
2007-08-10
IB070808-05
©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.